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Background:  Although low high density lipoprotein cholesterol (HDL-C) is associated with cardiovascular disease (CVD), it remains unclear 
whether raising HDL-C can reduce CVD risk. We studied the association between changes in HDL-C and subsequent risk of CVD hospitalization 
among patients with type 2 diabetes.
Methods:  We conducted an observational cohort study of 30,067 members of the Kaiser Permanente Northwest and Southeast regions who had 
type 2 diabetes, and had two HDL-C measurements 6-24 months apart in 2001-2006. After calculating change in HDL-C, we used the date of the 
2nd measurement as the index date and followed the patient cohort for up to 7.5 years (through 2009) to determine whether change in HDL-C was 
associated with subsequent CVD hospitalizations. We examined HDL-C change continuously, and also stratified patients into categories of change: 
increased HDL-C by 6.5mg/dl, decreased HDL-C by 6.5mg/dl, or remained within +/-6.4mg/dl. Cox regression analyses were adjusted for baseline 
HDL-C, demographic and clinical risk factors, comorbidities and use of pharmacologic agents.
Results:  Mean age was 60.9+12.6 years, 51% were men, and mean diabetes duration was 5.4+4.3 years. Over a mean follow-up of 55.8+23.8 
months, 3717 (12.4%) patients experienced a CVD hospitalization. After multivariable adjustment, higher baseline HDL-C was significantly 
associated with lower CVD risk (HR 0.93 per 5mg/dl, 95% CI 0.92-0.95) and each 5mg/dl increase in HDL-C was associated with a 5% CVD risk 
reduction (HR 0.95, 95% CI 0.93-0.97). In the adjusted analyses of categorized HDL-C, a 6.5mg/dl HDL-C decline was associated with significantly 
increased CVD risk of 15% (HR 1.15, 95% CI 1.05-1.27) while a 6.5mg/dl increase produced a statistically significant 10% CVD risk reduction (HR 
0.90, 95% CI 0.83-0.98) relative to individuals with stable HDL-C.
Conclusions:  Change in HDL-C and baseline HDL-C were independently associated with risk of CVD hospitalization among patients with type 2 
diabetes after accounting for other lipid levels and other known risk factors. These results suggest that therapies that raise HDL-C, or at least prevent 
its decline, may therefore reduce CVD morbidity.
